Based on the results of our study, further clinical studies should focus on the effectiveness and safety of Cadonilimab combined with Anlotinib in extensivestage SCLC patients of Metastatic organs≥ 2, PD1>50%, ethnic groups other than East Asian, and those from different geographic areas. Here, PDCD1 is linked to small cell lung carcinoma.